BioVaxys, BioElpida Collaborate to Produce Ovarian Cancer Vaccine

Vancouver, Canada-based BioVaxys Technology has struck a deal with BioElpida for production and aseptic packaging of BioVaxys’ ovarian cancer vaccine candidate, BXV-0918A, at its facility in Lyon, France.

BioVaxys is developing BVX-0918A with Spanish drugmaker ProCare Health Iberia, which expects to apply to the European Medicines Agency for compassionate use authorization later this year for stage 3/stage 4 ovarian cancer.

BioVaxys is also developing vaccines against ovarian cancer and the SARS-CoV-2 virus.